- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
BRCA2 Mutation: Poor Prognosis in Prostate Cancer
The study, published in the British Journal of Cancer, observed poor survival at the end of the follow-up period in men carrying the mutation, compared to non-carriers.
BRCA2
Among men with prostate cancer detected on screening, survival among those with a mutation in the gene is much poorer than in those without such a mutation, researchers report.
BRCA2
British Journal of Cancer
The findings suggest that mutation carriers may warrant additional treatments to improve their prognosis, say Steven Narod (Women’s College Hospital, Toronto, Ontario) and fellow authors writing in the .
BRCA2
BRCA2
mutations are known to confer an increased risk for developing prostate cancer and also to be associated with more aggressive tumours. However, the effect of mutations status on mortality in the setting of screen-detected cancers is unclear.
Original report: http://bit.ly/1yRJII4
Source: medwireNews
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
